Protease inhibitor levels in hair strongly predict virologie response to treatment

Monica Gandhi, Niloufar Ameli, Peter Bacchetti, Stephen J. Gange, Kathryn Anastos, Alexandra Levine, Charles L. Hyman, Mardge Cohen, Mary Young, Yong Huang, Ruth M. Greenblatt

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective: Antiretroviral (ARV) therapies fail when behavioral or biologic factors lead to inadequate medication exposure. The currently available methods to assess ARV exposure are limited. Levels of ARVs in hair reflect plasma concentrations over weeks to months, and may provide a novel method for predicting therapeutic responses. Design/methods: The Women's Interagency HIV Study, a prospective cohort of HIV-infected women, provided the basis for developing and assessing methods to measure commonly prescribed protease inhibitors (lopinavir/ritonavir and atazanavir) in small hair samples. We examined the association between hair protease inhibitor levels and initial virologic responses to therapy in multivariate logistic regression models. Results: ARV concentrations in hair were strongly and independently associated with treatment response for 224 women starting a new protease inhibitor-based regimen. For participants initiating lopinavir/ritonavir, the odds ratio (OR) for virologic suppression was 39.8 [95% confidence interval (CI) = 2.8-564] for those with lopinavir hair levels in the top tertile (>1.9 ng/mg) compared to the bottom (<0.41 ng/mg) when controlling for self-reported adherence, age, race, starting viral load and CD4 cell count, and prior experience with protease inhibitors. For women starting atazanavir, the adjusted OR for virologic success was 7.7 (95% CI = 2.0-29.7) for those with hair concentrations in the top tertile (>3.4 ng/mg) compared to the lowest (<1.2 ng/mg). Conclusion: Protease inhibitor levels in small hair samples were the strongest independent predictor of virologic success in a diverse group of HIV-infected adults. This non-invasive method for determining ARV exposure may have particular relevance for the epidemic in resource-poor settings due to the ease of collecting and storing hair.

Original languageEnglish (US)
Pages (from-to)471-478
Number of pages8
JournalAIDS
Volume23
Issue number4
DOIs
StatePublished - Feb 20 2009

Fingerprint

Protease Inhibitors
Hair
Lopinavir
Ritonavir
HIV
Therapeutics
Logistic Models
Biological Factors
Odds Ratio
Prospective Studies
Confidence Intervals

Keywords

  • Antiretroviral exposure
  • Atazanavir
  • Hair levels
  • Lopinavir
  • Protease inhibitors
  • Therapeutic drug monitoring
  • Virologic response
  • Women's interagency HIV study

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Gandhi, M., Ameli, N., Bacchetti, P., Gange, S. J., Anastos, K., Levine, A., ... Greenblatt, R. M. (2009). Protease inhibitor levels in hair strongly predict virologie response to treatment. AIDS, 23(4), 471-478. https://doi.org/10.1097/QAD.0b013e328325a4a9

Protease inhibitor levels in hair strongly predict virologie response to treatment. / Gandhi, Monica; Ameli, Niloufar; Bacchetti, Peter; Gange, Stephen J.; Anastos, Kathryn; Levine, Alexandra; Hyman, Charles L.; Cohen, Mardge; Young, Mary; Huang, Yong; Greenblatt, Ruth M.

In: AIDS, Vol. 23, No. 4, 20.02.2009, p. 471-478.

Research output: Contribution to journalArticle

Gandhi, M, Ameli, N, Bacchetti, P, Gange, SJ, Anastos, K, Levine, A, Hyman, CL, Cohen, M, Young, M, Huang, Y & Greenblatt, RM 2009, 'Protease inhibitor levels in hair strongly predict virologie response to treatment', AIDS, vol. 23, no. 4, pp. 471-478. https://doi.org/10.1097/QAD.0b013e328325a4a9
Gandhi, Monica ; Ameli, Niloufar ; Bacchetti, Peter ; Gange, Stephen J. ; Anastos, Kathryn ; Levine, Alexandra ; Hyman, Charles L. ; Cohen, Mardge ; Young, Mary ; Huang, Yong ; Greenblatt, Ruth M. / Protease inhibitor levels in hair strongly predict virologie response to treatment. In: AIDS. 2009 ; Vol. 23, No. 4. pp. 471-478.
@article{9fa2568df04f44658c6cbb7e23918bd3,
title = "Protease inhibitor levels in hair strongly predict virologie response to treatment",
abstract = "Objective: Antiretroviral (ARV) therapies fail when behavioral or biologic factors lead to inadequate medication exposure. The currently available methods to assess ARV exposure are limited. Levels of ARVs in hair reflect plasma concentrations over weeks to months, and may provide a novel method for predicting therapeutic responses. Design/methods: The Women's Interagency HIV Study, a prospective cohort of HIV-infected women, provided the basis for developing and assessing methods to measure commonly prescribed protease inhibitors (lopinavir/ritonavir and atazanavir) in small hair samples. We examined the association between hair protease inhibitor levels and initial virologic responses to therapy in multivariate logistic regression models. Results: ARV concentrations in hair were strongly and independently associated with treatment response for 224 women starting a new protease inhibitor-based regimen. For participants initiating lopinavir/ritonavir, the odds ratio (OR) for virologic suppression was 39.8 [95{\%} confidence interval (CI) = 2.8-564] for those with lopinavir hair levels in the top tertile (>1.9 ng/mg) compared to the bottom (<0.41 ng/mg) when controlling for self-reported adherence, age, race, starting viral load and CD4 cell count, and prior experience with protease inhibitors. For women starting atazanavir, the adjusted OR for virologic success was 7.7 (95{\%} CI = 2.0-29.7) for those with hair concentrations in the top tertile (>3.4 ng/mg) compared to the lowest (<1.2 ng/mg). Conclusion: Protease inhibitor levels in small hair samples were the strongest independent predictor of virologic success in a diverse group of HIV-infected adults. This non-invasive method for determining ARV exposure may have particular relevance for the epidemic in resource-poor settings due to the ease of collecting and storing hair.",
keywords = "Antiretroviral exposure, Atazanavir, Hair levels, Lopinavir, Protease inhibitors, Therapeutic drug monitoring, Virologic response, Women's interagency HIV study",
author = "Monica Gandhi and Niloufar Ameli and Peter Bacchetti and Gange, {Stephen J.} and Kathryn Anastos and Alexandra Levine and Hyman, {Charles L.} and Mardge Cohen and Mary Young and Yong Huang and Greenblatt, {Ruth M.}",
year = "2009",
month = "2",
day = "20",
doi = "10.1097/QAD.0b013e328325a4a9",
language = "English (US)",
volume = "23",
pages = "471--478",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Protease inhibitor levels in hair strongly predict virologie response to treatment

AU - Gandhi, Monica

AU - Ameli, Niloufar

AU - Bacchetti, Peter

AU - Gange, Stephen J.

AU - Anastos, Kathryn

AU - Levine, Alexandra

AU - Hyman, Charles L.

AU - Cohen, Mardge

AU - Young, Mary

AU - Huang, Yong

AU - Greenblatt, Ruth M.

PY - 2009/2/20

Y1 - 2009/2/20

N2 - Objective: Antiretroviral (ARV) therapies fail when behavioral or biologic factors lead to inadequate medication exposure. The currently available methods to assess ARV exposure are limited. Levels of ARVs in hair reflect plasma concentrations over weeks to months, and may provide a novel method for predicting therapeutic responses. Design/methods: The Women's Interagency HIV Study, a prospective cohort of HIV-infected women, provided the basis for developing and assessing methods to measure commonly prescribed protease inhibitors (lopinavir/ritonavir and atazanavir) in small hair samples. We examined the association between hair protease inhibitor levels and initial virologic responses to therapy in multivariate logistic regression models. Results: ARV concentrations in hair were strongly and independently associated with treatment response for 224 women starting a new protease inhibitor-based regimen. For participants initiating lopinavir/ritonavir, the odds ratio (OR) for virologic suppression was 39.8 [95% confidence interval (CI) = 2.8-564] for those with lopinavir hair levels in the top tertile (>1.9 ng/mg) compared to the bottom (<0.41 ng/mg) when controlling for self-reported adherence, age, race, starting viral load and CD4 cell count, and prior experience with protease inhibitors. For women starting atazanavir, the adjusted OR for virologic success was 7.7 (95% CI = 2.0-29.7) for those with hair concentrations in the top tertile (>3.4 ng/mg) compared to the lowest (<1.2 ng/mg). Conclusion: Protease inhibitor levels in small hair samples were the strongest independent predictor of virologic success in a diverse group of HIV-infected adults. This non-invasive method for determining ARV exposure may have particular relevance for the epidemic in resource-poor settings due to the ease of collecting and storing hair.

AB - Objective: Antiretroviral (ARV) therapies fail when behavioral or biologic factors lead to inadequate medication exposure. The currently available methods to assess ARV exposure are limited. Levels of ARVs in hair reflect plasma concentrations over weeks to months, and may provide a novel method for predicting therapeutic responses. Design/methods: The Women's Interagency HIV Study, a prospective cohort of HIV-infected women, provided the basis for developing and assessing methods to measure commonly prescribed protease inhibitors (lopinavir/ritonavir and atazanavir) in small hair samples. We examined the association between hair protease inhibitor levels and initial virologic responses to therapy in multivariate logistic regression models. Results: ARV concentrations in hair were strongly and independently associated with treatment response for 224 women starting a new protease inhibitor-based regimen. For participants initiating lopinavir/ritonavir, the odds ratio (OR) for virologic suppression was 39.8 [95% confidence interval (CI) = 2.8-564] for those with lopinavir hair levels in the top tertile (>1.9 ng/mg) compared to the bottom (<0.41 ng/mg) when controlling for self-reported adherence, age, race, starting viral load and CD4 cell count, and prior experience with protease inhibitors. For women starting atazanavir, the adjusted OR for virologic success was 7.7 (95% CI = 2.0-29.7) for those with hair concentrations in the top tertile (>3.4 ng/mg) compared to the lowest (<1.2 ng/mg). Conclusion: Protease inhibitor levels in small hair samples were the strongest independent predictor of virologic success in a diverse group of HIV-infected adults. This non-invasive method for determining ARV exposure may have particular relevance for the epidemic in resource-poor settings due to the ease of collecting and storing hair.

KW - Antiretroviral exposure

KW - Atazanavir

KW - Hair levels

KW - Lopinavir

KW - Protease inhibitors

KW - Therapeutic drug monitoring

KW - Virologic response

KW - Women's interagency HIV study

UR - http://www.scopus.com/inward/record.url?scp=62349118443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62349118443&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e328325a4a9

DO - 10.1097/QAD.0b013e328325a4a9

M3 - Article

C2 - 19165084

AN - SCOPUS:62349118443

VL - 23

SP - 471

EP - 478

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

ER -